EXACT-Tx announced that the phase I ACTIVATE study evaluating ACT in patients with metastatic colorectal cancer has successfully enrolled the first patient following temporary suspension due to the COVID-19 pandemic. To date 6 patients have now been enrolled in the study being led by Professor Udai Banerji at the Royal Marsden Hospital (RMH) in London. The first in man ACTIVATE study is a phase I evaluation of the innovative platform technology, Acoustic Cluster Therapy (ACT®) in the treatment of patients with metastatic colorectal and pancreatic cancer. This study is assessing the safety, tolerability and preliminary efficacy of ACT co-administered with standard of care chemotherapy in these patients. To date the study has enrolled 6 patients at RMH with Professor Udai Banerji as principal investigator. Additional centres in the UK and Norway are planned as the study progresses.